|
![]() |
|
|
Triazolam
drug data and news
Triazolam drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Triazolam | ||
| Brand Names/Synonyms | Alti-Triazolam; Apo-Triazo; CCRIS 1932; CHEMBANK1716; Clorazolam; Dea No. 2887; Gen-Triazolam; HSDB 6759; Halcion; Novidorm; Novo-Triolam; Novodorm; Songar; T7658; Triazolam; Triazolam 100 Ug Per Ml in Methanol; Triazolam [Usan:Ban:Inn:Jan]; Triazolamum [Inn-Latin] | ||
| Indication | For the short-term treatment of insomnia. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites. | ||
| Mechanism Of Action | Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. | ||
| Triazolam News (When available) |
Bristol-Myers Squibb and Gilead Sciences Submit New Drug ... Apr 27, 2006 Bristol-Myers Squibb Apr 27, 2006 | ||
| Dosage Forms | TABLET (0.125 mg, 0.25 mg) | ||
| Drug_Category | Anti-Anxiety Agents; Adjuvants, Anesthesia; GABA Modulators; Benzodiazepines; ATC:N05CD05 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Triazolam: Both pharmacodynamic and pharmacokinetic interactions have been reported with benzodiazepines. In particular, triazolam produces additive CNS depressant effects when coadministered with other psychotropic medications, anticonvulsants, antihistamines, ethanol, and other drugs which themselves produce CNS depression. Drugs that inhibit triazolam metabolism via cytochrome P450 3A: The initial step in triazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A). Drugs which inhibit this metabolic pathway may have a profound effect on the clearance of triazolam . Drugs and other substances demonstrated to be CYP 3A inhibitors of possible clinical significance on the basis of clinical studies involving triazolam (caution is recommended during coadministration with triazolam): IsoniazidóCoadministration of isoniazid increased the maximum plasma concentration of triazolam by 20%, decreased clearance by 42%, and increased half-life by 31%. Oral contraceptivesóCoadministration of oral contraceptives increased maximum plasma concentration by 6%, decreased clearance by 32%, and increased half-life by 16%. Grapefruit juiceóCoadministration of grapefruit juice increased the maximum plasma concentration of triazolam by 25%, increased the area under the concentration curve by 48%, and increased half-life by 18%. Drugs demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to triazolam or on the basis of in vitro studies with triazolam or other benzodiazepines (caution is recommended during coadministration with triazolam): Available data from clinic a l studies of benzodiazepines other than triazolam suggest a possible drug interaction with triazolam for the following: fluvoxamine, diltiazem, and verapamil. Data from in vitro studies of triazolam suggest a possible drug interact ion with triazolam for the following: sertraline and paroxetine. Data from in vitro studies of benzodiazepines other than triazolam suggest a possible drug interaction with triazolam for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine. Caution is recommended during coadministration of any of these drugs with triazolam. Drugs that affect triazolam pharmacokinetics by other mechanisms: RanitidineóCoadministration of ranitidine increased the maximum plasma concentration of triazolam by 30%, increased the area under the concentration curve by 27%, and increased half-life by 3.3%. Caution is recommended during coadministration with triazolam. | ||
| Toxicity | Symptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine | ||
| Chemical Formula | C17H12Cl2N4 | ||
| Molecular Weight | 343.21 g/mol | ||
| Smiles String | CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl | ||
| Melting Point | 233-235 °C | ||
| Water Solubility | 4.53 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 4.87 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. Small amounts of unmetabolized triazolam appear in the urine. | ||
| Half Life | 1.5-5.5 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Triazolam.html http://www.rxlist.com/cgi/generic/triazolam.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/hal1192.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00313 | ||
| CAS Registry Number | 28911-01-5 | ||
| KEGG Compound ID | D00387 | ||
| PubChem ID | SID:386391 | ||
| PharmGKB ID | PA451753 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2230024 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |